A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Trial Profile

A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Sep 2015 to 1 Dec 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2017.
    • 09 Feb 2015 Planned End Date changed from 1 Jul 2014 to 1 Sep 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top